Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

Core Insights - Wave Life Sciences Ltd. is set to host a live webcast and conference call on February 26, 2026, to discuss its fourth quarter and full year 2025 financial results and provide business updates [1]. Company Overview - Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines aimed at transforming human health [3]. - The company's RNA medicines platform, PRISM®, integrates various modalities and chemistry innovations to address both rare and common disorders [3]. - Wave's pipeline includes programs targeting obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), and PNPLA3 I148M liver disease (WVE-008), along with clinical programs for Duchenne muscular dystrophy and Huntington's disease [3]. - The company emphasizes its mission to "Reimagine Possible," striving to alleviate the burden of disease on human potential [3].